CellMax Life

CellMax Life and Sebela Pharmaceuticals Enter Strategic Development and Commercialization Partnership for FirstSig... prn.to/3w9m6Vc

Additional details around the FirstSight blood test in detecting precancerous colorectal adenomas were released at 2020 Virtual @ASCO, highlighting a significant association between blood test scores and polyps found in enrolled subjects by colonoscopy. bit.ly/2XPzCg7

We are excited to share #positivedata from our U.S. study evaluating the efficacy of our FirstSight blood test in detecting colorectal adenomas and #cancer. Access the full presentation released by Digestive Disease Week (DDW) here: lnkd.in/gckcA8C!

Thanks for visiting us at #DDW19 to learn about the #CellMaxLife blood test for Adenoma detection. Partner with us to make #colorectalcancer a preventable disease.

#CellMaxLife has developed the first blood test for adenoma detection that enables more diagnostic colonoscopies. Come by our Booth #4430 at #DDW19 to find out more.

Are you curious to learn about the blood test for Adenoma detection? Come by our Booth #4430 at #DDW19 to find out more about our FirstSight Blood Test.

Nature Publication @nresearchnews highlights utility of CellMax Life's circulating tumor cell (CTC) #liquidbiopsy "CMx" in solid tumors. CMx detected CTC cluster load associated with disease recurrence, lymph node metastasis and treatment response. #CancerResearch

Great audience engagement on #liquidbiopsy for precancer and early colorectal cancer at The Personalized Medicine World Congress #pmwc19 #stanfordmedicine

@FierceBiotech on our cell-based #liquidbiospy for precancer and colorectal cancer. Podium presentation at @ASCO's GI meeting. #GI19 fiercebiotech.com/medtech/cellma…

@cellmaxlife CMx technology for precancer/cancer cell detection to be used in colorectal cancer cell therapy clinical trial genomeweb.com/cancer/cellmax…

#Motleyfool on the potential of #CellMaxLife to "dethrone" non-invasive colorectal #cancerscreening incumbents with a simple blood test .... fool.com/investing/2018…

Thanks for visiting us at booth #804 at #AMP2018 to learn about the #CellMaxLife blood testing platform for pre-cancer and colorectal #cancer. Partner with us to make #colorectalcancer a preventable disease.

#CellMax's proprietory platform detects pre-cancerous adenomas before they become #colorectalcancer, using 1 tube of blood. Come by Booth #804 at #AMP2018 to learn about the platform that has been awarded 16 patents and was showcased on the #ASCO18 Podium!

DYK #Colorectalcancer is the most preventable, yet least prevented cancer. Come to Booth #804 at #AMP2018 to learn more about testing for pre-cancer

LISTEN: @HealthProRadio on the #CellMax blood test- the 1st and only blood test for pre-cancer detection enabling #colorectalcancer prevention. bit.ly/2xIwkhE

Our founder and CEO, Atul Sharan, is speaking @PMWCintl about CellMax Life's CTC blood test. #CellMaxCTC has demonstrated a high sensitivity for early cancer detection, unlike cfDNA and methylation-based methods that have demonstrated limited sensitivity for this purpose #PMWC18

For CTC testing CellMax has an innovative platform. Their PD-L1 data in CTCs correlates well with tissue PD-L1 by IHC. (AACR18-Hsieh) gives genomics as well.

Insightful article written by @biotechvisigoth at @MedCityNews, highlighting 6 new U.S. patents granted for our globally affordable and non-invasive #CellMaxCTC blood test to detect #colorectalcancer at its earliest stages: bit.ly/2uRQeq7

We are proud to announce 6 U.S. patents for our affordable #CellMaxCTC blood test for early detection and monitoring of cancer with an accuracy of 84 to 88% for colorectal cancer detection. bit.ly/2JNfcvm

Our ultra-sensitive CTC platform was granted 6 US patents. @Stanford Chief of Gastroenterology Shai Friedland sees potential for the platform to be the first line early colorectal cancer detection test for 100 million Americans eligible for screening. bit.ly/2JNfcvm